



(Supplement-SOlllh African Journal of Laboratory and Clinical Medicine)
8 overnber 1969
STUDIES ON THE CRYSTALLURIA POTENTIAL OF SULPHONAMIDES: ACETYLATION
OF SULPHADIMIDINE UNDER CONTROLLED ALKALINE URINE CONDITIONS
F. J. POTGIETER AND M. C. B. VAN OUDTSHOORN, Department of Pharmaceutics, Po/chefs/room University,
Po/chefs/room, Tv!
The kinetics of absorption, metabolism and excretion of
sulphonamides have been studied by examination of blood
and, in certain cases, urine.'" Studies on the acetylation
of sulphafurazole' and sulphamethylthiadiazole3 in human
test subjects indicate that excretion of the acetylated drug
is the terminal step in a two-step consecutive first-order
process Qf which the first step is acetylation. This was
also shown to be the case for sulphadimidine.'
Although the metabolism of sulphonamides is discussed
in standard textbooks, no attention is given to the fact
that the acetylation of sulphadimidine by man exhibits
genetic polymorphism.' It was shown that there are two
recognizable phenotypes, namely, rapid and slow acety-
la tors, and that slow acetylation is a Mendelian-recessive
character. In a recent publicaton we have described the
kinetic parameters for absorption and excretion of rapid
and slow acetylators of sulphadimidine:
The work reported now was conducted as part of a
programme on the evaluation of various pharmaceutical
dosage forms of sulphadimidine. The possibility of the
occurrence of crystalluria in the therapy with sulphona-
mides should always be considered, since its consequences
may be quite serious if precipitation of the drug occurs
in the kidney.
METHODS
A test panel of 4 healthy young male adults was used in
the study; 1·0 G sulphadimidine in the form of two com-
pressed tablets was ingested in the morning on stomachs
that had been fasted overnight. No food was taken until
2 hours after ingestion of the dose. Sufficient water was
taken to maintain an adequate urine flow. After drug
ingestion quantitative urine collections were obtained at
intervals as shown in Table I. Free and total sulphona-
mide concentrations in urine were estimated by the Brat-
ton-MarshalI' procedure. Alkaline urine conditions were
maintained with an alkali load of 2·0 G of sodium bi-
carbonate every 3 hours.
RESULTS AND DISCUSSION
The mInImum urine flow-rate needed to prevent the oc-
currence of cry talluria may be calculated by the following
expression.'
Minimum flow-rate = Excretion rate/Solubility.
In this expression excretion rate refers to the acetylsul-
phadimidine expected to precipitate and is taken to be
in units of mg./hr. If solubility is taken in units of mg./
mJ., then minimum flow-rate will be in units of mI./hr.·
The solubility of acetylsulphadimidine at pH 7 and 37"C
was taken as 1-45 mg. / mJ.'o
The minimum flow-rates calculated using the above
expression for the 4 test subjects are given in Table I.
Using the method described by White and Evans,"
subject C was phenotyped as a rapid acetylator of sulpha-
dimidine with an acetylation of more than 80o~. From
the results in Table I it can be seen that the excretion rate
of acetylated drug for subject C is considerably higher
than for the other 3 test subjects; a much higher urine
flow-rate is also necessary.
At a dose level of 3·0 G, which is recommended as the
initial dose for sulphadimidine, a much higher urine flow-
rate is necessary and a much higher excretion rate of ace-
tylated drug can be expected. Special attention should be
given to the urine flow-rate of a rapid acetylator of sul-
phadimidine even under controlled alkaline urine
conditions.
SUMMARY
Using a single oral dose of 1-0 G of sulphadimidine as 2 com-
pressed tablets, different concentrations of acetylsulphadimidine
were recovered in the urine after 48 hours. One test subject
was phenotyped as a rapid acetylator of sulphadimidine with
an acetylation of more than 80%. The minimum urine flow-
rate needed to prevent the occurrence of crystalluria due to
precipitation of 'N acetylated drug is calculated for 4 test
subjects.
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TABLE J. MINIMUM URINE FLOW-RATE NECESSARY TO PREVENT CRYSTALL RIA FOLLOWING 1· O-G ORAL DOSE OF SULPHADIMIDINE AT pH 7
Excrerioll rate of acetylaied drug (mg./hr) Flow-rate (ml.jllr)
Time
Subjecr Subject Subject Subject Subject Subject Subject Subject
A B C D A B C D
0-1 4·1 0 7·6 0 2·8 0 5·2 0
1-2 6·6 6·2 45·9 2·0 4·5 4·3 31·7 1·4
2-3 15·1 14·0 79·8 11·2 10·4 9·7 55·0 7·7
3-4 12·2 15·9 77·7 14·7 8·4 11·0 53·6 10·1
4-5 14·8 21·2 83·5 24·7 10·2 14·6 57·6 17·0
5-6 22·6 16·5 ·2 22· 15·6 11·3 53·9 15·7
6-9 17·7 24·4 61 ·7 31·9 12·2 16·8 42·6 22·0
9-12 23·6 29·3 46·4 0·9 16·3 20·2 32·0 0·6
12-24 13·0 11·1 8'5 13·3 9·0 7·7 5·9 9·2
24-36 9,' 7·1 2·3 4,' 6·3 4·9 1·6 2·8
36-4 2·8 ],2 0'5 0·1 1·9 0·8 C·3 0,]
% acetylation 64'8% 61'8% 86'90% 66'3%
